Dual topoisomerase I/II poisons as anticancer drugs

Bibliography

• OSHEROFF N: Biochemical basis for the interactions of type land type II topoisomerases with DNA. Pharmacol, Ther. (1989) 41:223–241.
   PubMed Web of Science ®Google Scholar
• GUPTA M, FUJIMORI A, POMMIER Y: Eukaryotic topoi-somerase I. Biochim, Biophys, Acta (1995) 1262:1–14.
   PubMed Web of Science ®Google Scholar
• GIACCONE G: Small cell lung cancer and topoi-somerases. Anticancer Research (1994) 14:269–276.
   PubMed Web of Science ®Google Scholar
• LIMA CD, WANG JC, MONDRAGON A: Three-dimensionalstructure of the 67K N-terminal fragment of E. con DNA topoisomerase I. Nature (1994) 367:138–146.
   PubMed Web of Science ®Google Scholar
• BERGER JM, HAMBLIN SJ, HARRISON SC, WANG JC: Struc-ture and mechanism of DNA topoisomerase II. Nature (1996) 379:225–232.
   PubMed Web of Science ®Google Scholar
• NELSON EM, TEWEY KM, LIU LF: Mechanism of antitu-mor drug action: poisoning of mammalian DNA topoi-somerase II on DNA by 4'-(9-acridinylamino)-methanesulfon-m-anisidide. Proc. Natl. Acad. Sci, USA (1984) 81:1361–1365.
   PubMed Web of Science ®Google Scholar
• POMMIER Y: DNA topoisomerases and their inhibitionby anthracyclines. In: AnthracyclineAntibiotics: NewAna-logues, Methods of Delivery and Mechanisms of Action. Priebe W (Ed.), ACS Symposium Series 574, American Chemical Society (1995):183–203.
   Google Scholar
• POMMIER Y, LETEURTRE F, FESEN MR et at: Cellular de-terminants of sensitivity and resistance to topoi-somerase inhibitors. Cancer Invest. (1994) 12:530–542.
   PubMed Web of Science ®Google Scholar
• HUSAIN I, MOHLER JL, SEIGLER HF, BESTERMAN JM: Ele- vation of topoisomerase I messenger RNA, protein, and catalytic activity in human tumors: demonstration of tumor-type specificity and implications for cancer che-motherapy. Cancer Res. (1994) 54:539–546.
   PubMed Web of Science ®Google Scholar
• ••Suggested relationships between topo I levels and efficacy oftherapy with topo I agents.
   Google Scholar
• HOLDEN JA, ROLFSON DH, WITTWER CT: Human DNA to- poisomerase II: evaluation of enzyme activity in nor-mal and neoplastic tissues. Biochemistry (1990) 29:2127–2134.
   PubMed Web of Science ®Google Scholar
• GIOVANELLA B, STEHLIN JS, WALL ME et al.: DNA topoi-somerase I targeted chemotherapy of human colon cancer in xenografts. Science (1989) 246:1046–1048.
   PubMed Web of Science ®Google Scholar
• HECK MMS, HITTELMAN WN, EARNSHAW WC: Differen-tial expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc. Natl. Acad. Sci, USA (1988) 85:1086–1090.
   PubMed Web of Science ®Google Scholar
• TAN KB, MATTERN MR, ENG W-K, MCCABE FL, JOHNSONRK: Nonproductive rearrangement of DNA topoi-somerase I and II genes: correlation with resistance to topoisomerase inhibitors. J. Natl. Cancer Inst. (1989) 81:1732–1735.
   PubMed Web of Science ®Google Scholar
• SUGIMOTO Y, TSUKAHARA S, OH-HARA T, ISOE T, TSU-RUO T: Decreased expression of DNA topoisomerase I in camptothecin-resistant tumor cell lines as deter-mined by a monoclonal antibody. Cancer Res. (1990) 50:6925–6930.
   PubMed Web of Science ®Google Scholar
• WHITACRE CM, ZBOROWSKA E, GORDON NH, MACKAYW, BERGER NA: Topotecan increases topoisomerase Ha levels and sensitivity to treatment with etoposide in schedule-dependent process. Cancer Res. (1997) 57:1425–1428.
   PubMed Web of Science ®Google Scholar
• •Evidence of inter-relationship of topo land topo II resistance.
   Google Scholar
• CROW RT, CROTHERS DM: Inhibition of topoisomerase I by anthracycline antibiotics: evidence for general inhi-bition of topoisomerase I by DNA-binding agents. J. Med. Chem. (1994) 37:3191–3194.
   PubMed Web of Science ®Google Scholar
• YAMASHITA Y, KAWADA S, FUJI N, NAKANO H: Induction of mammalian DNA topoisomerase I and II mediated DNA cleavage by saintopin, a new antitumor agent from fungus. Biochemistry (1991) 30:5838–5845.
   PubMed Web of Science ®Google Scholar
• TANIGUCHI K, KOHNO K, KAWANAMI K et al.: Drug-induced down-regulation of topoisomerase I in human epidermoid cancer cells resistant to saintopin and camptothecins. Cancer Res. (1996) 56:2348–2354.
   PubMed Web of Science ®Google Scholar
• LETEURTRE F, KOHLHAGEN G, FESEN M et al.: Effects of DNA methylation on topoisomerase I and II cleavage activities. J. Biol. Chem. (1993) 269:7893–7900.
   Web of Science ®Google Scholar
• FUJII N, YAMASHITA Y, MIZUKAMI T, NAKANO H: Corre-lation between the formation of cleavable complex with topoisomerase and growth-inhibitory activity for saintopin-type antibiotics. Mol. Pharmacol. (1997) 51:269–276.
   PubMed Web of Science ®Google Scholar
• PODDEVIN B, RIOU J-F, LAVELLE F, POMMIER Y: Dual to-poisomerase I and II inhibition by intoplicine (RP-60475), a new antitumor agent in early clinical trials. MoL Pharmacol. (1993) 44:767–774.
   PubMed Web of Science ®Google Scholar
• RIOU J-F, FOSSE P, NGUYEN CH et al.: Intoplicine (RP 60475) and its derivatives, a new class of antitumor agents inhibiting both topoisomerase land II activities. Cancer Res. (1993) 53:5987–5993.
   PubMed Web of Science ®Google Scholar
• NABIEV I, CHOURPA I, RIOU JF et al.: Molecular interac- tions of DNA-topoisomerase land II inhibitor with DNA and topoisomerases and in ternary complexes: binding modes and biological effects for intoplicine derivative. Biochemistry (1994) 33:9013–9023.
   PubMed Web of Science ®Google Scholar
• ••Data linking different DNA binding modes to topo I and II in-teractions.
   Google Scholar
• ECKARDT JR, BURRIS HA, KUHN JG et al.: Activity of in-toplicine (RP 60475), a new DNA topoisomerase land II inhibitor, against human tumor colony-forming units in vitro. J. Natl. Cancer Inst. (1994) 86:30–33.
   PubMed Web of Science ®Google Scholar
• ABIGERGES D, ARMAND JP, CHABOT GG et al.: Phase Iand pharmacology study of intoplicine (RP 60475, NSC 645008), a novel topoisomerase I and II inhibitor, in cancer patients. Anticancer Drugs (1996) 7:166–174.
   PubMed Web of Science ®Google Scholar
• UTSUGI T, AOYAKI K, FURUNE Y et al.: Antitumor activityof TAS-103, a novel topoisomerase I and II inhibitor. Proc. Am. Assoc. Cancer Res. (1996) 37:427. Abstract 2915.
   Google Scholar
• ISHIDA T, NISHIO K, ARIOKA HN et al.: Cytotoxic mecha-nisms of a novel DNA topoisomerase I and II dual in-hibitor, TAS-103. Proc. Am. Assoc. Cancer Res. (1997) 38:21. Abstract 137.
   Google Scholar
• ISHIDA T, NISHIO K, ARIOKA H et al.: TAS-103, a noveldual inhibitor of DNA topoisomerase land II. Proc. Am. Assoc. Cancer Res. (1996) 37:428. Abstract 2922.
   Google Scholar
• LARSEN, AK, GRONDARD L, COUPRIE J et al.: The antileu-kemic alkaloid fagaronine is an inhibitor of DNA topoi-somerases I and II. Biochem. Pharmacol. (1993) 46:1403–1412.
   PubMed Web of Science ®Google Scholar
• GATTO B, SANDERS MM, YU C et al.: Identification of to-poisomerase I as the cytotoxic target of the protober-be r ine alkaloid coralyne. Cancer Res. (1996) 56:2795–2800.
   PubMed Web of Science ®Google Scholar
• WANG LK, JOHNSON RK, HECHT SM: Inhibition of topoi-somerase I function by nitidine and fagaronine. Chem. Res. Tox. (1993) 6:813–818.
   PubMed Web of Science ®Google Scholar
• KANZAWA F, ISHIDA T, FUKUDA M, NISHIO K, SAIJO N:Antitumor activities of a new benzo[c]phenanthridine agent, NK109, against several drug-resistant carcinoma lines. Proc. Am. Assoc. Cancer Res. (1996) 37:427. Abstract 2916.
   Google Scholar
• KABASAWA T, KOBAYASHI F, EKIMOTO H et al.: A novelbenzo[c]phenanthridine derivative, NK109, is a highly active anticancer agent and DNA topoisomerase II in-hibitor. Proc. Am. Assoc. Cancer Res. (1996) 37:427. Abstract 2917.
   Google Scholar
• MAKHEY DB, YU C, LIU A, LIU LF, LAVOIE EJ: Substitutedbenz[a]acridines and benz[c]acridines as mammalian topoisomerase poisons. Proc. Am. Assoc. Cancer Res. (1997) 38:22. Abstract 144.
   Google Scholar
• BAILLY C, RIOU J-F, COLSON P et al.: DNA cleavage by to-poisomerase I in the presence of indolocarbazole de-rivatives of rebeccamycin. Biochemistry (1997) 36:3917–3929.
   PubMed Web of Science ®Google Scholar
• ••Structure-activity studies for indolocarbazoles for topo I poi-soning.
   Google Scholar
• WEITMAN S, MOORE R, BARRERA HL, HILSENBECK S, VONHOFF DD: Preclinical activity of rebbecamycin ana-logue against pediatric solid tumors. Proc. Am. Assoc. Cancer Res. (1997) 38:610. Abstract 4095.
   Google Scholar
• PEREIRA ER, BELIN L, SANCELME M et al.: Structure-activity relationships in a series of substituted indolo-carbazoles - topoisomerase land protein kinase C inhi-bition and antitumoral and antimicrobial properties. J. Med. Chem. (1996) 39:4471–4477.
   PubMed Web of Science ®Google Scholar
• •Structure-activity studies for topo I poisoning by indolocar-bazoles.
   Google Scholar
• YOSHINARI T, YAMADA A, UEMURA D et al.: Induction oftopoisomerase I mediated DNA cleavage by a new in-dolocarbazole, ED-110. Cancer Res. (1993) 53:490–494.
   PubMed Web of Science ®Google Scholar
• YOSHINARI T, MATSUMOTO M, ARAKAWA H et al.: Novelantitumor indolocarbazole compound 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13- (13-D--glucopyranosyl)-511-indolo[2, 3-a]pyrolo-[3,4-c]carbazole-5,7(611)-dione (NB-506): induction of topoisomerase I-mediated DNA cleavage and mecha-nisms of cell line-selective cytotoxicity. Cancer Res. (1995) 55:1310–1315.
   PubMed Web of Science ®Google Scholar
• •In-depth study of NB-506.
   Google Scholar
• KANZAWA F, NISHIO K, KUBOTA N, SAIJO N: Antitumoractivities of a new indolocarbazole substance, NB-506, and establishment of NB-506-resistant cell lines, SBC-3/NB. Cancer Res. (1995) 55:2806–2813.
   PubMed Web of Science ®Google Scholar
• LONG BH, FAIRCHILD CA, BIFANO M, KRAMER R: The cy-totoxic mechanism of NB-506 involves action on both topoisomerase I and topoisomerase II. Proc. Am. Assoc. Cancer Res. (1997) 38:75. Abstract 508.
   Google Scholar
• FUKUDA M, NISHIO K, KANZAWA F et al.: Synergism be-tween cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells. Cancer Res. (1996) 56:789–793.
   PubMed Web of Science ®Google Scholar
• MEIKLE I, CUMMINGS J, MACPHERSON JS, HADFIELD JA,SMYTH JF: Biochemistry of topoisomerase land II inhi-bition by anthracenyl-amino acid conjugates. Biochem. Pharmacol. (1995) 49:1747–1757.
   PubMed Web of Science ®Google Scholar
• CUMMINGS J, MACPHERSON JS, MEIKLE I, SMYTH JF: De-velopment of anthracenyl-amino acid conjugates as to-poisomerase I and II inhibitors that circumvent drug resistance. Biochem. Pharmacol. (1996) 52:979–990.
   PubMed Web of Science ®Google Scholar
• MEIKLE I, CUMMINGS J, MACPHERSON JS, SMYTH JF: In-dentification of anthracenyl-dipeptide conjugates as novel topoisomerase I and II inhibitors and their evaluation as potential anticancer drugs. Anticancer Drug Design (1995) 10:515–527.
   PubMedGoogle Scholar
• ATWELL GJ, REWCASTLE GW, BAGULEY BC, DENNY WA:Potential antitumor agents. 50. In vivo solid tumor ac-tivity of derivatives of N42-(dimethyl-amino)ethyllacridine-4-carboxamide. I Med. Chem. (1987) 30:664–669.
   Google Scholar
• SCHNEIDER E, DARKIN SA, LAWSON PA et al.: Cell line se-lectivity and DNA breakage properties of the antitu-mour agent N42-(dimethylamino)ethyllacridine-4-carboxamide: role of DNA topoisomerase II. Eur. J. Cancer Clin. Oncol. (1988) 24:1783–1790.
   PubMedGoogle Scholar
• FINLAY GJ, RIOU J-F, BAGULEY BC: From amsacrine to DACA (N42-(dimethylamino)ethyllacridine-4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur. J. Cancer (1996) 32A:708–714.
   PubMed Web of Science ®Google Scholar
• ••Structure-activity relationships with respect to selective topoI/II activity by acridines.
   Google Scholar
• SPICER JA, GAMAGE SA, ATWELL GJ et al.: Structure-activity relationships for acridine-substituted ana-logues of the mixed topo I/II inhibitor A/42-(dimethyl-amino)ethyllacridine-4-carboxamide WACO J Med Chem. (1997) 40: 1919-1929.
   Google Scholar
• DAVEY RA, SU GM, HARGRAVE RM et al.: The potential of/1/[2-(dimethylamino)ethyllacridine-4-carboxamide to circumvent three multidrug-resistance phenotypes. Cancer Chemother. PharmacoL (1997) 39:424–430.
   PubMed Web of Science ®Google Scholar
• BOUSQUET PF, BRANA MF, CONLON D et al.: Preclinicalevaluation of LU 79553: a novel bis-naphthalimide with potent antitumor activity. Cancer Res. (1995) 55:1176–1180.
   PubMed Web of Science ®Google Scholar
• BRANA MF, CASTELLANO JM, MORAN M et al.: Bis-naphthalimides 3: synthesis and antitumor activity of N,N-bis[2-(1,8-naphthalimido)-ethyl]alkanediamines. Anticancer Drug Design (1996) 11:297–309.
   PubMedGoogle Scholar
• BRANA MF, CASTELLANO JM, PERRON D et al.: Chromophore-modified bis-naphthalimides: synthesis and antitumor activity of bis-dibenz[de,h]isoquinoline-1,3-diones. J. Med. Chem. (1997) 40:449–454.
   PubMed Web of Science ®Google Scholar
• •A new class of bis(naphthalimides) and some biochemical data.
   Google Scholar
• BAILLY C, BRANA MF, WARING MJ: Sequence-selective in- tercalation of antitumor bis-naphthalimides into DNA. Evidence for an approach via the major groove. Eur. J. Biochem. (1996) 240:195–208.
   PubMedGoogle Scholar
• MCRIPLEY RJ, BURNS-HORWITZ PE, CZERNIAK PM et al.: Efficacy of DMP 840: a novel bis-naphthalimide cyto-toxic agent with human solid tumor xenograft selectiv-ity. Cancer Res. (1994) 54:159–164.
   PubMed Web of Science ®Google Scholar
• HOUGHTON PJ, CHESHIRE PJ, HALLMAN JC et al.: Evalua-tion of a novel bis-naphthalimide anticancer agent, DMP-840, against human xenografts derived from adult, juvenile, and pediatric cancers. Cancer Chemo-then Pharmacol. (1994) 33:265–272.
   PubMed Web of Science ®Google Scholar
• ROBINSON CP, ROBINSON KA, CASTANER J: Bisnafide mesylate. Antineoplastic DMP-840 (NSC D640430). Drugs Future (1996) 21:239–244.
   Google Scholar
• CHERNEY RJ, SWARTZ SG, PATTEN AD et al.: The synthe-sis and antitumor evaluation of unsymmetrical bis-imides. Bioorg. Med. Chem. Lett. (1997) 7:163–168.
   Web of Science ®Google Scholar
• KIRSHENBAUM MR, CHEN SF, BEHRENS CH et al.: (R,R)-2,2'41,2-ethanediylbis[imino(1-methyl-2,1-ethanediy1)]1- bis[5-nitro-1 H-benz[de]- isoquinoline-1,3- (214)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tu-moricidal activity in vitro. Cancer Res. (1994) 54:2199–2206.
   PubMed Web of Science ®Google Scholar